Moreover, when the PAM pathway is inhibited, compensatory pathways interconnected with the PAM pathway, such as the estrogen receptor (ER) pathway, the mitogen-activated protein kinases (MAPK) pathway, and the cyclin-dependent kinases (CDK) pathway, can drive tumor progression [3,16]. Here, ESR1 is linked to neoplasm.